Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Wire Jailing at Side Branch to Prevent Occlusion After Main Vessel Stenting: Should It Be the Standard of Care?

While the ideal treatment for coronary bifurcation is provisional stenting, this can be associated with side branch occlusion, which leads to severe adverse events. To prevent this complication, several treatments have been proposed. One of them is wire jailing at side branch before stent implantation in the main vessel. However, the actual benefit of this strategy has not yet been evaluated.

Enjaular la cuerda en la rama lateral para prevenir oclusión luego del stent en el vaso principal, ¿debemos hacerlo rutinariamente?

The aim of this study was to evaluate the angiographic and clinical impact of wire jailing prior to main vessel stenting (second-generation stent).

The primary endpoint was side branch occlusion after stent implantation, defined as a Thrombolysis In Myocardial Infarction (TIMI) flow grade <3. The secondary endpoint included 1) treated-lesion failure, defined as cardiovascular death, acute myocardial infarction, and lesion revascularization; 2) treated-lesion failure only, and 3) angiographic and procedural success.

Researchers conducted an analysis of COBIS III (Coronary Bifurcation Stenting), a retrospective, multicenter, observational registry. A total of 1890 patients who met the inclusion criteria were included and divided into two groups: the wire jailing group (N = 819, 43%), and the non-wire jailing group (N = 1071, 56%).

There was no difference between populations. Mean patient age was 63 years old, and around 70% were male. Half the patients were hypertensive and 30% suffered from diabetes mellitus. The wire jailing group had higher rates of true bifurcation lesions and left main coronary artery disease.

Read also: Provisional vs Dual Stenting in Left Main: An Endless Discussion?

The most frequent presentation was acute coronary syndrome.

There were no significant differences in the primary endpoint (wire jailing 1.8% vs. non-wire jailing 2.9%; hazard ratio [HR]: 0.62; 95% confidence interval [CI]: 0.33-1.16; p = 0.133) or the secondary endpoint. Furthermore, there was no difference in angiographic and procedural success, nor in patient follow-up (mean of 52 months).

There were significant differences in side branch occlusion in patients with >60% stenosis in side branch or main vessel (HR: 0.30; 95% CI: 0.12-0.69; p = 0.007), in favor of those with guidewire use on the secondary branch.

Conclusion

In the 1-stent strategy for the treatment of bifurcation lesions with second-generation stents, wire jailing the side branch before main vessel stenting was associated with a decrease in the rate of side branch occlusion in patients with severe lesions in the main vessel or side branch, but there were no differences in all types of bifurcations or in long-term clinical follow-up.

Randomized studies are needed to clarify the role of this technique.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org

Original Title: Effect of Wire Jailing at Side Branch in 1-Stent Strategy for Coronary Bifurcation Lesions

Reference: Yeon-Jik Choi et al. J Am Coll Cardiol Intv. 2022 Feb, 15 (4) 443–455.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...